<span style="line-height: 20.8px;">South San Francisco-based&nbsp;</span><span style="line-height: 20.8px;">Denali Therapeutics Inc</span><span style="line-height: 20.8px;">, which is focused on developing treatments for patients with neurodegenerative diseases, has raised $130 million in Series B financing.&nbsp;</span><span style="line-height: 20.8px;">Baillie Gifford</span><span style="line-height: 20.8px;">&nbsp;led the round with participation from other investors that included&nbsp;</span><span style="line-height: 20.8px;">ARCH Venture Partners, F-Prime Biosciences, Flagship Ventures</span><span style="line-height: 20.8px;">&nbsp;and the&nbsp;</span><span style="line-height: 20.8px;">Alaska Permanent Fund</span><span style="line-height: 20.8px;">.</span>